Effect of Mazdutide on Coronary Plaque in Patients With Coronary Atherosclerosis and Overweight or Obesity
NCT07657676 on ClinicalTrials.gov · last registry update 2026-08-28
Registered but not yet open, with 116 participants planned. Due to report 31 December 2027, alongside 38 other tracked readouts that quarter. Primary outcome, as filed: Change in total non-calcified plaque volume (NCPV) by CCTA from baseline to 52 weeks. Sponsors move these dates routinely; any movement since this site started watching is listed below. mazdutide is not approved in the US for anything yet, so this is a drug in development rather than an established treatment being extended. The registry entry has been edited 1 time since then.
- Status
- NOT_YET_RECRUITING
- Phase
- P4
- Drug
- mazdutide
- Sponsor
- China National Center for Cardiovascular Diseases
- Sponsor type
- Other Gov
- Enrollment
- 116
- Started
- 2026-09-01
- Primary completion
- 2027-12-31 estimated
Observed history
Every change this record has made since we started watching it. ClinicalTrials.gov shows only the current value. When a field is edited the previous one is overwritten and nothing is published to say so, so this history exists only because someone was recording it at the time.
| Detected | Change | Detail |
|---|---|---|
| 2026-08-28 | Reporting date moved | 2027-10-31 → 2027-12-31 2 months later |
Primary outcome
Change in total non-calcified plaque volume (NCPV) by CCTA from baseline to 52 weeks
Conditions studied
Obesity & Overweight · Coronary Heart Disease
Every field above is taken directly from the registry record. See all detected changes across the class, or the mazdutide page for this molecule’s full trial and approval history.